Glenmede Trust Co. NA Buys 180,890 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Glenmede Trust Co. NA grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 144.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,511 shares of the medical research company’s stock after acquiring an additional 180,890 shares during the period. Glenmede Trust Co. NA owned 0.17% of IQVIA worth $72,634,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of IQV. First Foundation Advisors increased its holdings in IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares in the last quarter. Invera Wealth Advisors LLC grew its holdings in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares in the last quarter. Private Trust Co. NA lifted its stake in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares during the last quarter. Finally, Continuum Advisory LLC grew its stake in shares of IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after acquiring an additional 49 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Truist Financial lowered their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Barclays dropped their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Down 1.4 %

Shares of IQVIA stock opened at $201.24 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $36.53 billion, a PE ratio of 26.41, a PEG ratio of 2.10 and a beta of 1.51. The firm has a 50-day moving average of $221.18 and a 200-day moving average of $226.75. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.